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Objective: To assess the effect of amlodipine and atorvastatin on intercellular adhesion
molecule (ICAM)-1 and tumor necrosis factor (TNF)-α expression, as endothelial function
and inflammation indicators, respectively, in hypertensive patients with and without
prediabetes.
Methods: Forty-five consecutive patients with hypertension, diagnosed according to
JNC7, were divided into two groups based on the presence (HD group, n = 23)
or absence (H group, n = 22) of prediabetes, diagnosed according to 2010 ADA
criteria, including impaired glucose tolerance (IGT) and fasting glucose tests. All
patients simultaneously underwent 12-week treatment with daily single-pill amlodipine
besylate/atorvastatin calcium combination (5/10 mg; Hisun-Pfizer Pharmaceuticals Co.
Ltd). Serum isolated before and after treatment from overnight fasting blood samples
was analyzed by ELISA.
Results: In the HD and H groups after vs. before 12-week amlodipine/atorvastatin
treatment, there were significantly (all P < 0.01) lower levels of ICAM-1 (3.06 ± 0.34
vs. 4.07 ± 0.70 pg/ml; 3.26 ± 0.32 vs. 3.81 ± 0.60 pg/ml, respectively) and TNF-α
(78.71 ± 9.19 vs. 110.94 ± 10.71 pg/ml; 80.95 ± 9.33 vs. 101.79 ± 11.72 pg/ml,
respectively), with more pronounced reductions in HD vs. H group (ICAM-1∆:
1.01 ± 0.80 vs. 0.55 ± 0.64 pg/ml, respectively, P = 0.037; TNF-α∆: 32.23 ± 14.33
vs. 20.84 ± 14.89 pg/ml, respectively, P = 0.011), independent of the blood pressure
(BP) and cholesterol level reduction.
Conclusions: Amlodipine/atorvastatin improved endothelial function and inflammation,
as reflected by lower circulating levels of ICAM-1 and TNF-α, more prominently in
hypertensives with than without prediabetes. Starting statin treatment before overt
diabetes in hypertensives might thus improve cardiovascular outcomes.
Keywords: amlodipine and atorvastatin calcium, prediabetes, hypertension, inflammation, endothelial
dysfunction, intercellular adhesion molecule-1, tumor necrosis factor-α
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INTRODUCTION
Atherosclerosis, the leading cause of death worldwide, is
associated with endothelial dysfunction and inflammation
(Libby, 2002; Davignon and Ganz, 2004), with hypertension
and prediabetes playing crucial pathogenic roles by increasing
secretion of adhesion molecules and inflammatory cytokines
(Magen et al., 2010; DeFronzo and Abdul-Ghani, 2011).
Overall, 25.9–69.3% of individuals have at least one known
risk factor for atherosclerosis, including hypertension, diabetes,
dyslipidemia, smoking, and obesity (Rosamond et al., 2007).
Hypertension, its most common risk factor, accounts for
about half of the global atherosclerosis morbidity and
mortality (Ezzati et al., 2005), and a sizable proportion of
patients with essential hypertension suffer from prediabetes
(García-Puig et al., 2006; Gu et al., 2012), with increased
blood glucose levels, both fasting and postprandial, even
below the threshold levels of diabetes diagnostic criteria,
increasing cardiovascular mortality (Levitan et al., 2004).
The hemodynamic changes induced by hypertension lead
to endothelial dysfunction, with increased serum levels
of inflammation factors such as tumor necrosis factor-α
(TNF-α), and expression of adhesion molecules including
intercellular adhesion molecules-1 (ICAM-1) further enhancing
monocyte/macrophage migration into the vascular wall and
promoting atherosclerosis and inflammation, which is further
aggravated by other risk factors such as prediabetes (Chapman
and Sposito, 2008).
Statins competitively inhibit HMG-CoA reductase and exhibit
various pleiotropic effects which attenuate inflammation and
improve endothelial function as reflected by decreased levels
of TNF-α and ICAM-1 independent of blood lipid level
reduction (Ascer et al., 2004; Davignon, 2004; Landsberger et al.,
2007). The European Society of Cardiology (ESC)/European
Atherosclerosis Society (EAS) guidelines for the management of
dyslipidemias therefore recommend statin treatment in patients
with hypertension and diabetes regardless of basal lipid level
to reduce cardiovascular disease (CVD) risks (Catapano et al.,
2011). However, it is unknown whether the latter benefit
extends to patients with hypertension and prediabetes, for
whom there are scant data on the effects of statin plus anti-
hypertensive therapy. The present study therefore investigated
the effect of a single-pill combination of amlodipine and
atorvastatin calcium on the circulating levels of ICAM-1




All 45 study subjects were enrolled from the cardiovascular
outpatient clinic between April 2012 and November 2013,
and all assessments were completed. Study exclusion criteria
were: coronary heart disease; stroke; secondary hypertension;
diabetes; liver disease; rheumatological, neoplastic or other
endocrine disease; serum creatinine concentration >1.20 mg/dl;
severe dyslipidemia (serum low density lipoprotein-cholesterol
(LDL-c) ≥160 mg/dl; total cholesterol (Tc) ≥240 mg/dl or
triglycerides >200 mg/dl; recent acute illness; neuropathy;
or participation in other clinical trials. Overall, age range
was 45–67 years, and no subject had been treated for CVD
or other risk factors. Twenty-two hypertensive subjects
(H group) and 23 hypertensive prediabetic subjects (HD
group) were studied. Hypertension was defined as stage 1
hypertension, i.e., systolic blood pressure (SBP) ≥140 mmHg
and <160 mmHg, and diastolic blood pressure (DBP)
≥90 mmHg and <100 mmHg (Chobanian et al., 2003).
Blood pressure (BP) was measured twice with a standardized
mercury manometer after the subject rested for at least 15 min;
the mean of two measurements was used for the analysis.
Prediabetes was diagnosed according to 2010 ADA criteria
including impaired fasting glucose (IFG) or/and impaired
glucose tolerance (IGT; American Diabetes Association, 2010)
tests.
Study Design
All eligible subjects underwent blood testing at baseline, after
which all were treated daily with a single-pill combination
of amlodipine besylate atorvastatin calcium (5/10 mg; Hisun-
Pfizer Pharmaceuticals Co. Ltd). All subjects received dietary
instructions, and liver function and creatine kinase level were
monitored for potential side effects of statins. After 12 weeks
of treatment, all subjects underwent blood testing. The study
primary outcomewas the changes of circulating levels of ICAM-1
and TNF-α after 12 weeks’ treatment compared with before.
The study conformed to the guidelines set forth in the Helsinki
declaration, and the protocol was approved by the Medical
Ethics Committee of the first affiliated hospital of Wenzhou
Medical University. All patients provided written informed
consent.
Laboratory Measurements
All laboratory experiments were carried out after an overnight
fast. Blood samples were drawn from an antecubital vein
and collected in ethylene diaminetetraacetic acid tubes. Blood
specimens were centrifuged at 3000 rpm for 10 min, and
the serum was separated and stored at −80◦C until analysis.
Serum levels of fasting glucose (Glu), glycosylated hemoglobin
(HbA1c), 2 h-glucose (2 h-Glu), Tc, LDL-c, alanine amino
transferase (ALT) and creatinine (Cr) were determined in
the laboratory of the First Affiliated Hospital of Wenzhou
Medical University. Serum levels of ICAM-1 and TNF-α,
serving as indicators of endothelial function and inflammation,
respectively were assessed using commercially available enzyme-
linked immunoassay kits in accordance with the manufacturer’s
instructions (Bio-Swamp and Rapidbio).
Statistical Analysis
Normal distribution of the data was tested using
Kolmogorov–Smirnov test. All the data were normally
distributed. Continuous data are presented as mean ± SD, and
were compared using paired samples T-test and independent
samples T-test. Bivariate correlation analysis was performed
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TABLE 1 | Baseline clinical characteristics by study group.
Hypertension Hypertension
alone (H) and prediabetes (HD)
Male/Female 14/8 19/4
Age, years 53.68 ± 5.07 55.09 ± 6.80
BMI, kg/m2 24.84 ± 1.97 25.04 ± 2.17
Smoking, (%) 21.20% 22.90%
Alcohol use, (%) 43.50% 42.10%
SBP, mmHg 147.00 ± 5.67 149.74 ± 6.77
DBP, mmHg 92.86 ± 5.86 95.30 ± 8.00
Glu, mmol/L 5.27 ± 0.25 6.03 ± 0.44∗
2 h-Glu, mmol/L 6.10 ± 0.90 8.04 ± 1.43∗
HbA1c, (%) 5.48 ± 0.26 5.90 ± 0.33∗
Tc, mmol/L 5.67 ± 0.41 5.60 ± 0.70
LDL-c, mmol/L 3.45 ± 0.32 3.30 ± 0.52
ALT, U/L 28.50 ± 12.37 28.70 ± 15.18
Cr, µmol/L 63.18 ± 13.95 69.48 ± 11.05
Data are presented as mean ± SD or as percentages. ∗P < 0.01, compared with
baseline H. Otherwise, P-values were not significant.
to explore the relation among ICAM-1, TNF-α, BP, Tc and
LDL-c. The 0.05 level of probability was set as being statistically
significant. All analyses were performed with the SPSS (version
20.0) statistical package.
RESULTS
Baseline Characteristics of Study
Participants
As shown in Table 1, there were no significant differences in the
distributions of clinical and metabolic characteristics of study
participants between H and HD groups except for glucose and
HbA1c levels.
The Effect of the Combination Treatment
With Amlodipine and Atorvastatin Calcium
on BP and Blood Lipid Levels in Both
Study Groups
The 12-week treatment with the single-pill combination
of amlodipine 5 mg and atorvastatin calcium
FIGURE 1 | Comparisons of reductions in Blood pressure (BP) and
blood lipid levels between study groups. All P > 0.05.
10 mg daily significantly reduced (P < 0.01)
BP and blood lipid levels in H and HD groups
(Table 2) to a statistically similar extent (P > 0.05;
Figure 1).
The Effect of the Single-Pill, Amlodipine
and Atorvastatin Calcium Treatment on
ICAM-1 and TNF-α Levels in Hypertensive
Patients With or Without Prediabetes
As shown in Figure 2, after 12 weeks of treatment
with the single-pill combination of amlodipine 5 mg
and atorvastatin calcium 10 mg daily, ICAM-1 level
significantly (P < 0.01) decreased by 14.44% in the H
group (from 3.81 ± 0.60 pg/ml to 3.26 ± 0.32 pg/ml), and
by 24.82% in the HD group (from 4.07 ± 0.70 pg/ml to
3.06 ± 0.34 pg/ml). TNF-α level also significantly (P < 0.01)
decreased after treatment by 20.47% in the H group (from
101.79 ± 11.72 pg/ml to 80.95 ± 9.33 pg/ml), and by
TABLE 2 | Clinical parameters by study group before and after treatment.
Hypertension (H) Hypertensive prediabetes (HD)
Baseline 12 weeks Baseline 12 weeks
SBP, mmHg 147.00 ± 5.67 136.77 ± 6.91# 149.74 ± 6.77 137.17 ± 4.84>
DBP, mmHg 92.86 ± 5.86 84.50 ± 5.91# 95.30 ± 8.00 84.70 ± 4.64>
Glu, mmol/L 5.27 ± 0.25 5.25 ± 0.36 6.03 ± 0.44 6.13 ± 0.54
2 h-Glu, mmol/L 6.10 ± 0.90 NA 8.04 ± 1.43 NA
HbA1c, (%) 5.48 ± 0.26 5.45 ± 0.25 5.90 ± 0.33 5.94 ± 0.30
Tc, mmol/L 5.67 ± 0.41 3.98 ± 0.80# 5.60 ± 0.70 3.94 ± 0.88>
LDL-c, mmol/L 3.45 ± 0.32 2.07 ± 0.65# 3.30 ± 0.52 1.95 ± 0.54>
ALT, U/L 28.50 ± 12.37 32.95 ± 15.55 28.70 ± 15.18 39.0 ± 27.50
Cr, µmol/L 63.18 ± 13.95 62.95 ± 14.66 69.48 ± 11.05 67.43 ± 13.67
Data are presented as mean ± SD. #P < 0.01, compared with baseline H. >P < 0.01, compared with baseline HD. NA, not applicable.
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FIGURE 2 | Comparison between serum levels of biomarkers before
and after treatment. ¤P < 0.01, compared with baseline.
29.05% in the HD group (from 110.94 ± 10.71 pg/ml to
78.71± 9.19 pg/ml).
The Difference of the Treatment’s Effect on
ICAM-1 and TNF-α Levels in Hypertensive
Patients With and Without Prediabetes
Comparative analysis of the changes in ICAM-1 (IACM-
1∆) and TNF-α (TNF-α∆) levels between the H group
and the HD groups revealed a more pronounced decrease
in the HD group (ICAM-1∆: 0.55 ± 0.64 pg/ml to
1.01 ± 0.80 pg/ml, P = 0.037; TNF-α∆: 20.84 ± 14.89 pg/ml
to 32.23 ± 14.33 pg/ml, P = 0.011, respectively,
Figure 3).
The Relation Between the Effect of
Combined Treatment on Serum
Biomarkers for Endothelial Function and
Inflammation and BP and Cholesterol
Levels
In bivariate correlation analysis, no significant correlations
were apparent in either group between changes in
FIGURE 3 | Comparisons between treatment-associated reductions in
biomarker levels between the two study groups. §P = 0.037,
§§P = 0.011, compared with H∆.
TABLE 3 | Bivariate correlation analysis of treatment associated changes
in serum intercellular adhesion molecule (ICAM)-1 and tumor necrosis
factor (TNF)-α relative to those in blood pressure (BP), total cholesterol
(Tc), and low density lipoprotein-cholesterol (LDL-c) levels.
SBP∆ DBP∆ Tc∆ LDL-c∆
r P r P r P r P
ICAM-1∆ 0.27 0.07 0.28 0.06 −0.24 0.12 −0.22 0.15
TNF-α∆ 0.28 0.07 0.08 0.59 0.15 0.32 0.17 0.28
∆ denotes change in the corresponding indicator.
ICAM-1 or TNF-α levels and changes in BP, Tc or LDL-c
(Table 3).
DISCUSSION
The main findings of the present single center study were as
follows: (1) patients with hypertension either with or without
prediabetes appeared to benefit from treatment with single-
pill combination of amlodipine 5 mg and atorvastatin calcium
10 mg, as reflected by significant reductions in ICAM-1
and TNF-α levels; and (2) said reductions in ICAM-1 and
TNF-α levels were more pronounced in hypertensives with than
without prediabetes, and independent of BP or cholesterol level
reductions.
Our previous study had already shown that hypertensive
prediabetics experienced unfavorable shifts toward higher levels
of serum levels of ICAM-1 and TNF-α when compared with
patients with isolated hypertension, suggesting a higher risk
for CVD and warranting investigation of appropriate treatment
interventions. The results of the present study are consistent
with those of a study using an animal model, in which
amlodipine plus atorvastatin significantly reduced TNF-α levels
(Kawai et al., 2011; Zhang et al., 2012), and with the results
of the MARGAUX study in which the said combination
treatment significantly reduced the levels of adhesion molecules
in human coronary disease (Charbonneau et al., 2008). The
ASCOT-LLA study had shown important and large relative
reductions in the rates of cardiovascular events associated with
the additional use of atorvastatin 10 mg among hypertensive
patients who were at moderate cardiovascular risk (hypertension
with at least three cardiovascular risk factors; Sever et al.,
2003). While the population in the present study was at
lower risk (only age >45 years, hypertension or smoking as
risk factors), short-term treatment of hypertensives with or
without prediabetes with amlodipine plus atorvastatin calcium
was enough to reduce ICAM-1 and TNF-α levels, with
the effect being more pronounced in the presence of both
conditions, indicating that use of this combination in such
lower risk population can also improve endothelial function
and inflammation. The latter anti-inflammatory effects appeared
independent of the cholesterol and BP lowering effect of
the combination treatment. Indeed, no significant correlation
was found between the changes in TNF-α or ICAM-1 levels
and the reduction in blood lipid levels of BP produced by
the single-pill combination of amlodipine and atorvastatin
calcium in the present study. The latter pleiotropic effects of
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amlodipine plus atorvastatin may contribute to the reported
positive effect of statins (Schwartz et al., 2001; Fogari et al.,
2006).
LIMITATIONS
Interpretation of the results of the present study is limited by
its single center, nonrandomized design with a relatively small
sample size. Further larger, multicenter, randomized studies are
warranted.
CONCLUSION
In the present single center, non-randomized, small study,
combined treatment with amlodipine and atorvastatin appeared
to have a beneficial effect on endothelial function and
inflammation, as reflected by reductions in serum ICAM-1
and TNF-α levels in hypertensives with or without prediabetes,
with the effect being more pronounced in the former.
Based on the latter findings, one could posit that starting
statin treatment before overt diabetes becomes apparent in
hypertensive patients with prediabetes might result in better
cardiovascular outcomes, which needs to be tested in larger
studies.
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